Integrating Systemic and Local Therapy: Recent Clinical Trial Updates (Results of Clinical trials) (IASGO 2026) - Sep 23, 2026 - Abstract #SY35-3; Pres time: Sep 11, 2026; 01:40 PM - 03:10 PM; "The REGATTA trial, an open-label, randomized phase III studyconducted in Korea, Japan, and Singapore, evaluated whether gastrectomy followed by chemotherapy(S-1 plus cisplatin) was superior to chemotherapy alone in patients with AGC and a single noncurablefactor involving the liver, peritoneum, or para-aortic lymph nodes...The Neo-REGATTA trial conducted in China evaluated docetaxel, oxaliplatin, andS-1 (the DOS regimen) followed by radical resection versus chemotherapy alone in patients withadvanced gastric adenocarcinoma and a single noncurable factor...In the prospective phase II AIO-FLOT3 trial, patients with limitedmetastatic disease received four cycles of neoadjuvant FLOT (fluorouracil, leucovorin, oxaliplatin, anddocetaxel) followed by surgical resection...More recently, the addition of molecularly targeted agents (e.g., trastuzumab andzolbetuximab) or immune checkpoint inhibitors (e.g., nivolumab, pembrolizumab, and tislelizumab) toconventional two- or..."
Clinical • Gastric Adenocarcinoma • Gastric Cancer • Solid Tumor
|